CTLA4 and pancreatitis: Furthermore, we observed no significant increase in the risk of grade 3–5 pancreatitis in the CTLA-4 inhibitor subgroup (versus chemotherapy/placebo, RR = 2.13, 95% CI: 0.80–5.67, p = 0.130), in the PD-1 inhibitor subgroup (versus chemotherapy, RR = 1.68, 95% CI: 0.51–5.60, p = 0.395; versus ipilimumab, RR = 1.54, 95% CI: 0.19–12.50, p = 0.685), in the combination treatment of nivolumab and ipilimumab subgroup (versus ipilimumab, RR = 3.55, 95% CI: 0.81–15.52, p = 0.093), and in the PD-1/PD-L1 inhibitor subgroup (versus chemotherapy, RR 1.37, 95% CI: 0.44–4.22, p = 0.584).